Clinical trial · Interventional
Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
The Efficacy of Induction Chemotherapy With Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma
NCT03427359CI-TRIAL-00031611completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To prospectively evaluate the short-term efficacy and toxicity of induction chemotherapy with cisplatin and capecitabine followed by concurrent chemoradiotherapy (CCRT) in the treatment of locally advanced nasopharyngeal carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin, capecitabine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- experimental arm
- description
- Induction chemotherapy: capecitabine tablet 1000mg/m2 po bid from day1 to 14,cisplatin injection 80mg/m2 iv day1,every 3 weeks for a total of 3 cycles. Then followed by concurrent chemoradiotherapy with cisplatin injection 100mg/m2 iv every 3 weeks for a total of 2 cycles.
- interventionNames
- Drug: cisplatin, capecitabine
Primary outcomes (1)
- measure
- PFS (progression free survival)
- timeFrame
- From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.
- description
- progression free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological confirmed nasopharyngeal carcinoma. * Staged as III to IVB. * 18-75 years old. * Performance status ≤2. * No previous chemotherapy or radiotherapy. * No concurrent malignancies or a history of other malignancies. * Adequate bone marrow function (absolute neutrophil count ≥1.5×109/L, platelets ≥100×109/L). * Adequate liver and renal function (serum bilirubin and serum transaminase levels less than twice the upper limit of normal, creatinine clearance ≥ 60ml/min). * Without serious co-morbidity. Exclusion Criteria: * Stage I-II or IVC. * Allergic to cisplatin or capecitabine * Age \<18 or \>75 * Performance Status \>2. * Without adequate bone marrow or liver function or renal function. * Severe co-morbidity and can not tolerate chemotherapy. * Other conditions not suitable for the study on the discretion of charging doctor.
References
Publications (0)
Data not yet available
No reference posted for this study.